



KARNATAKA ANTIBIOTICS AND PHARMACEUTICALS LIMITED
CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2022

(Rupees in Lakhs)

Particulars	For the year ended 31-Mar-22	For the year ended 31-Mar-21
A. Cash flow from operating activities		
Net profit before tax	3251.62	3074.08
Adjustments for non cash & Non operating items:		
Depreciation and amortization	813.95	739.26
Interest received from Banks	(219.98)	(137.02)
Interest expenses	64.35	73.73
Excess provision reversed	(2.24)	(24.12)
Provision for Contingencies	178.31	30.00
Provision for Doubtful debts	149.31	117.45
Provision made/(withdrawn)for slow moving/non moving inventory	12.59	(24.65)
Loss on sale Fixed Assets	2.40	-
Unrealised Foreign Exchange Loss (Gain)	(4.25)	3.45
Sundry Credit balances written back	(0.32)	(198.85)
Operating profit before working capital changes:	4245.74	3653.33
<i>Changes in working capital</i>		
Decrease / (Increase) in Inventories	(1954.14)	(707.76)
Decrease / (Increase) in Trade and Other Receivables	(7499.58)	6393.22
(Decrease) / Increase in Trade Payables and Other Liabilities	3428.78	(1717.14)
Cash generated from operations	(1,779.20)	7,621.65
Income taxes paid	(863.54)	(938.38)
Net cash generated by operating activities	(2,642.74)	6,683.27
B. Cash flow from investing activities		
Purchase of PPE, Capital WIP, Capital Advances	(602.80)	(621.75)
Proceed from sale of PPE	39.53	
Government Grant received	0.00	20.00
Interest received from Banks	219.98	137.02
Net cash from investing activities	(343.29)	(464.73)
C. Cash flow from financing activities		
Interest paid	(64.35)	(73.73)
Repayment of Long Term Borrowings	(300.00)	(300.00)
Increase/(Decrease) in short term Borrowings	0.68	(362.34)
Payment of Lease Liabilities including Interest	(53.87)	0.00
Dividend paid on equity shares	(404.71)	(377.72)
Net cash from financing activities	(822.25)	(1113.79)
D. Net changes in cash and cash equivalents (A + B + C)	(3,808.28)	5,104.75
Cash and cash equivalents at the beginning of the year	8298.39	3193.64
Cash and cash equivalents at the end of the year	4490.11	8298.39
Reconciliation of Cash and Cash equivalents with the Balance Sheet		
Cash and Cash equivalents as per Balance Sheet	1,164.63	3,505.48
Add: Bank Balances not considered as Cash and Cash Equivalents as defined in IND AS 7 Cash Flow Statement	3,325.48	4,792.91
Net Cash and Cash Equivalents	4,490.11	8,298.39
Cash and Cash equivalents at the end of the year Comprises (also refer note No 9 & 10)		
a) Cash on hand	0.50	0.31
b) In cash Credit	473.87	1,925.91
c) In fixed deposit account	3,890.16	6,299.28
d) In fixed deposit account-Margin Money	125.58	72.89

Significant Accounting Policies and accompanying Notes No. 1 to 51 form an integral part of the Financial Statement

This is the Cash Flow Statement referred to in Audit Report of even date
For Yoganandh & Ram LLP
Chartered Accountants
FRN: 005157S/5200052

Manoj Kumar Jain
Partner
Membership No. 218610



Date: 21st July 2022
Place: Bengaluru

For and on behalf of Board of Directors of
Karnataka Antibiotics and Pharmaceuticals Ltd
CIN: U24231KA1981GOI004145

Sunil Kumar Kaimal
Managing Director
DIN:0008528088

B T Khanapure
Director
DIN :000778686

Jagadish C.
Assistant General Manager- Finance

Supriya Kulkarni
Company Secretary

